Skip to main content
Harmony Biosciences Holdings, Inc. (HRMY)
NASDAQ: HRMY · IEX Real-Time Price · USD
29.32
+0.39 (1.35%)
Apr 26, 2024, 4:00 PM EDT - Market closed

HRMY Revenue

In the year 2023, Harmony Biosciences Holdings had annual revenue of $582.02M with 32.93% growth. Revenue in the quarter ending December 31, 2023 was $168.41M with 31.26% year-over-year growth.

Revenue (ttm)
$582.02M
Revenue Growth
+32.93%
P/S Ratio
2.86
Revenue / Employee
$2,365,943
Employees
246
Market Cap
1.66B USD

Revenue Chart

History

Fiscal Year End Revenue Change Growth
Dec 31, 2023582.02M144.17M32.93%
Dec 31, 2022437.86M132.42M43.35%
Dec 31, 2021305.44M145.70M91.21%
Dec 31, 2020159.74M153.75M2,564.59%
Dec 31, 20196.00M--
Dec 31, 20180--
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name Revenue
Myriad Genetics 753.20M
Supernus Pharmaceuticals 607.52M
Alphatec Holdings 482.26M
UFP Technologies 400.07M
Catalyst Pharmaceuticals 398.20M
Beam Therapeutics 377.71M
Schrödinger 216.67M
Avadel Pharmaceuticals 27.96M
Revenue Rankings

HRMY News

More News